| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1995;92:1779-1785.)
© 1995 American Heart Association, Inc.
Articles |
Some Coronary Risk Factors Related to the Insulin Resistance Syndrome and Treatment With Gemfibrozil
Experience From the Helsinki Heart Study
From the Helsinki Heart Study (L.T.), Helsinki, Finland; and First Department of Medicine (M.M., V.M.), University of Helsinki, Finland.
Correspondence to Leena Tenkanen, PhD, Helsinki Heart Study, Kalliolinnantie 4, SF-00140 Helsinki, Finland.
Background Coronary risk factors related to the insulin resistance syndrome tend to cluster in the same individual. Our previous studies have shown that the dyslipidemia characteristic of this syndrome—low HDL cholesterol and high triglyceride (TG) levels—responds well to treatment with gemfibrozil. Most factors related to insulin-resistance syndrome decrease fibrinolytic capacity, whereas a recent study showed that gemfibrozil improves it and thus may attenuate thrombotic events. To discover whether subjects with clustering of factors related to this resistance might in particular benefit from gemfibrozil, we reanalyzed the Helsinki Heart Study data.
Methods and Results We used Cox regression models to explore the
effects of gemfibrozil among overweight subjects with additional
coronary risk factors in this
hypercholesterolemic male population of 2046
subjects randomized to gemfibrozil and 2035 to placebo. The effect of
gemfibrozil was largely confined to overweight subjects: among those
with body mass index (BMI) >26 kg/m2, the net
difference in cardiac end points between gemfibrozil and placebo groups
was 21 (25 of 1119 versus 46 of 1081), and in those with BMI 
26
kg/m2, it was 7 (31 of 927 versus 38 of 954). The
risk reduction with gemfibrozil was 78% (P=.002) among
those with BMI >26 kg/m2 and
dyslipidemia (TG 
2.3 mmol/L and HDL
cholesterol <1.08 mmol/L). Among those with BMI >26
kg/m2 and three or four of the following factors
present—smoking, sedentary lifestyle, blood pressure 140/90
mm Hg, or blood glucose >4.4 mmol/L—the risk reduction was 68%
(P=.03).
Conclusions Gemfibrozil reduced the coronary risk mainly in overweight subjects with additional risk factors known to contribute to the insulin-resistance syndrome or predispose to it.
Key Words: obesity • exercise • smoking • infarction • lipoproteins
This article has been cited by other articles:
 |
|
 |
|
  J.-C. Fruchart, F. M Sacks, M. P Hermans, G. Assmann, W V. Brown, R. Ceska, M J. Chapman, P. M Dodson, P. Fioretto, H. N Ginsberg, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients Diabetes and Vascular Disease Research, November 1, 2008; 5(4): 319 - 335. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Pedro-Botet Review: The role of fenofibrate in reducing cardiovascular risk in type 2 diabetes The British Journal of Diabetes & Vascular Disease, January 1, 2008; 8(1): 22 - 27. [Abstract] [PDF]
|
|
|
|
|
|
A. S Wierzbicki Fibrates after the FIELD study: some answers, more questions Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 166 - 171. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Menard and J.-L. Ardilouze Multitherapy for diabetes Can. Med. Assoc. J., November 7, 2006; 175(10): 1247 - 1247. [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Wierzbicki Diabetic dyslipidaemia: the triad Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F30 - F33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. E. Bloomfield The role of fibrates in a statin world. Arch Intern Med, April 10, 2006; 166(7): 715 - 716. [Full Text] [PDF]
|
|
|
|
|
|
L. Tenkanen, M. Manttari, P. T. Kovanen, H. Virkkunen, and V. Manninen Gemfibrozil in the Treatment of Dyslipidemia: An 18-Year Mortality Follow-up of the Helsinki Heart Study. Arch Intern Med, April 10, 2006; 166(7): 743 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barter and K.-A. Rye Cardioprotective Properties of Fibrates: Which Fibrate, Which Patients, What Mechanism? Circulation, March 28, 2006; 113(12): 1553 - 1555. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rizzo and K. Berneis Low-density lipoprotein size and cardiovascular risk assessment QJM, January 1, 2006; 99(1): 1 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M J. Chapman Review: Fibrates: therapeutic review The British Journal of Diabetes & Vascular Disease, January 1, 2006; 6(1): 11 - 19. [Abstract] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Second World Congress on the Insulin Resistance Syndrome: Hypertension, cardiovascular disease, and treatment approaches Diabetes Care, August 1, 2005; 28(8): 2073 - 2080. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Staels and J.-C. Fruchart Therapeutic Roles of Peroxisome Proliferator-Activated Receptor Agonists Diabetes, August 1, 2005; 54(8): 2460 - 2470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.J. Barter Cardioprotective Effects of High-Density Lipoproteins: The Evidence Strengthens Arterioscler Thromb Vasc Biol, July 1, 2005; 25(7): 1305 - 1306. [Full Text] [PDF]
|
|
|
|
|
|
P.J. Barter Antiatherogenic Properties of Fibrates Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1095 - 1096. [Full Text] [PDF]
|
|
|
|
 |
|
 G. F Watts Treating low HDL-cholesterol in normocholesterolaemic patients with coronary disease: statins, fibrates or horses for courses? Eur. Heart J., May 1, 2004; 25(9): 716 - 719. [Full Text] [PDF]
|
|
|
|
|
|
P. Barter Review: Reconsidering the value of fibrates: lessons from the trials The British Journal of Diabetes & Vascular Disease, May 1, 2003; 3(3): 162 - 167. [Abstract] [PDF]
|
|
|
|
|
|
S. J. Robins, H. B. Rubins, F. H. Faas, E. J. Schaefer, M. B. Elam, J. W. Anderson, and D. Collins Insulin Resistance and Cardiovascular Events With Low HDL Cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT) Diabetes Care, May 1, 2003; 26(5): 1513 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Rubins, S. J. Robins, D. Collins, D. B. Nelson, M. B. Elam, E. J. Schaefer, F. H. Faas, J. W. Anderson, and for the VA-HIT Study Group Diabetes, Plasma Insulin, and Cardiovascular Disease: Subgroup Analysis From the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Arch Intern Med, December 9, 2002; 162(22): 2597 - 2604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.B. Rubins, D. Collins, and S.J. Robins The VA HDL Intervention Trial: clinical implications Eur. Heart J., July 2, 2000; 21(14): 1113 - 1115. [PDF]
|
|
|
|
|
|
M. Haim, M. Benderly, D. Brunner, S. Behar, E. Graff, H. Reicher-Reiss, and U. Goldbourt Elevated Serum Triglyceride Levels and Long-Term Mortality in Patients With Coronary Heart Disease : The Bezafibrate Infarction Prevention (BIP) Registry Circulation, August 3, 1999; 100(5): 475 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J.-C. Fruchart Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism Circulation, November 10, 1998; 98(19): 2088 - 2093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Nordt, K. Kornas, K. Peter, S. Fujii, B. E. Sobel, W. Kubler, and C. Bode Attenuation by Gemfibrozil of Expression of Plasminogen Activator Inhibitor Type 1 Induced by Insulin and its Precursors Circulation, February 4, 1997; 95(3): 677 - 683. [Abstract] [Full Text]
|
|
|
|
|
|
J. Arts, M. Kockx, H. M.G. Princen, and T. Kooistra Studies on the Mechanism of Fibrate-Inhibited Expression of Plasminogen Activator Inhibitor-1 in Cultured Hepatocytes From Cynomolgus Monkey Arterioscler Thromb Vasc Biol, January 1, 1997; 17(1): 26 - 32. [Abstract] [Full Text]
|
|
|
|
|
|
H. R. Superko Beyond LDL Cholesterol Reduction Circulation, November 15, 1996; 94(10): 2351 - 2354. [Full Text]
|
|
|
|
|
|
H. R. Lijnen and D. Collen Impaired Fibrinolysis and the Risk for Coronary Heart Disease Circulation, November 1, 1996; 94(9): 2052 - 2054. [Full Text]
|
|